Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ironwood’s Phase III Data Could Expand Linzess Market Share

Executive Summary

The company also hopes that positive safety data for pediatric patients could help with discussions with the FDA to make an OTC version of the drug.

You may also be interested in...

Ironwood Phase III Data Emphasizes Likely Linzess Label Expansion

Ironwood presented Phase III data on Linzess (linaclotide) at Digestive Disease Week for the treatment of 6-17 year-olds with functional constipation; US FDA approval is expected in a month.

Teva Pays Out A Further $1m On Intuniv

Teva will pay out more than $1m as part of a settlement deal over Intuniv (guanfacine) involving indirect purchasers, newly-filed court documents reveal. Meanwhile, the firm has also just gained a 2029 entry date for a 72mcg strength of its linaclotide rival to Linzess through a separate settlement.

Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts